Financing ·
Akari Therapeutics, Plc amended its existing securities purchase agreement to consolidate the second and third…
AKTXAkari Therapeutics Plc
Akari Therapeutics, Plc amended its existing securities purchase agreement to consolidate the second and third tranches of a private placement into a single closing. The original agreement involved the sale of 1,470,588 American Depository Shares (ADSs) or prefunded warrants, plus Series H, I, and J warrants. Following the first closing on May 27, 2026, the amendment rescheduled the remaining two tranches to a combined closing on June 26, 2026, where the company issued the remaining 980,395 ADSs or prefunded warrants. Issuance of the Series Warrants remains contingent upon shareholder approval at the June 30, 2026, annual general meeting. Akari Therapeutics is a biopharmaceutical company.